NSCLC (Non-small Cell Lung Carcinoma) Recruiting Phase 1 / 2 Trials for Itacitinib (DB12154)

IndicationStatusPhase
DBCOND0103105 (NSCLC (Non-small Cell Lung Carcinoma))Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02917993An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung CancerTreatment